Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04281498
Title Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Michal Bar-Natan
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Mayo Clinic - Arizona Scottsdale Arizona 85259 United States Details
Cedars-Sinai Medical Center Los Angeles California 90048 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
University of Kansas Cancer Center Westwood Kansas 66205 United States Details
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109-5936 United States Details
Icahn School of Medicine at Mount Sinai New York New York 10029 United States Details
Memorial Sloan-Kettering Cancer Center New York New York 10065 United States Details
Wake Forest Baptist Health Winston-Salem North Carolina 27157 United States Details
Taussig Cancer Center Institute Cleveland Ohio 44195 United States Details
Mays Cancer Center at UT Health San Antonio San Antonio Texas 78229 United States Details
Princess Margaret Cancer Centre Toronto M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from for the field